Lijie Tan

9PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSocial epidemiologyHaematological tumoursGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 02, 2026
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.

Yushang Yang, Xiaolong Yan, Hongjing Jiang

|Feb 17, 2026
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Jun Okui, Satoru Matsuda, Kengo Nagashima

|Jan 25, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in China.

Chunji Chen, Chang Yuan, Zhichao Liu

|Jan 07, 2026
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials.

Jun Okui, Satoru Matsuda, Kengo Nagashima

|Jul 02, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Jianjun Qin, Liyan Xue, Anlin Hao

|Sep 16, 2023
Telocytes protect against lung tissue fibrosis through hexokinase 2-dependent pathway by secreting hepatocyte growth factor.

Shaoyuan Zhang, Linyi Sun, Borong Chen

Pageof 2

Frequent Collaborators

4 joint publications

Shaoyuan Zhang

3 joint publications

Siyun Lin

2 joint publications

Kengo Nagashima

2 joint publications

Hirofumi Kawakubo